THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA

Abstract

ABSTRACTC-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactiveprotein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis,ischemic vascular diseases, type 2 diabetes mellitus, hypertension and colon cancer. Data evaluating theconcentration of CRP in hyperprolactinemic condition and the effect of bromocriptine on CRP concentration are notavailable. Thus the present study was designed to measure the concentration of CRP in a number of women withhyperprolactinemic amenorrhea and to evaluate the effect of bromocriptine on CRP concentration. The study tackledsixty women, who had amenorrhea for at least three months and serum prolactin concentration at least twice theupper limit of normal values. Bromocriptine is administered in a daily dose of 2 (2.5 mg) tablets. Serum prolactin andserum CRP were assessed before and after bromocriptine administration, using commercial kits. Mean CRPconcentration of the control group was 1.38±1.85 mg/L which is statistically lower than value of 6.35±4.62 mg/L ofthe patients before bromocripine therapy (P<0.001). A significant drop of CRP (from a mean of 6.35±4.62 mg/L to amean of 2.73±3.14 mg/L) was obtained after treatment with bromocriptine (P<0.001). The correlation betweenserum prolactin level and serum CRP level before and after bromocriptine administration was not statisticallysignificant: r= 0.24, P>0.05 and r = 0.12, P>0.2, respectively. The present study showed that women withhyperprolactinemic amenorrhea is associated with increased level of CRP and therapy with bromocriptinesignificantly reduced CRP, suggesting a possible anti-inflammatory action of bromocriptine in addition to prolactinlowering effects.